ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1509	National Cancer Institute	Html	en	Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.	actuarial survival rate 0.630338 significantly higher incidence 0.497662 survival rates 0.647886 excellent survival rates 0.613575 ovarian cystic neoplasms 0.524669 large series 0.505974 advanced-stage tumors 0.534809 survival rate 0.991192 serous tumors 0.508069 aggressive cytoreductive surgery 0.508958 intraperitoneal disease 0.508061 gross residual tumor 0.624183 DNA ploidy 0.473971 presumed localized tumors 0.627355 primary serous tumor 0.543013 patients 0.874529 gross residual disease. 0.554008 small bowel obstruction 0.517717 20-year survival rates 0.623524 total abdominal hysterectomy 0.500134 malignant potential tumors 0.654434 epithelial ovarian cancers 0.560469 positive lymph nodes 0.513754 secondary cytoreductive procedure 0.496028 malignant invasive carcinomas 0.598953	Oncology Group study 0.492475 borderline ovarian tumors 0.602765 early-stage disease 0.53696 borderline tumors 0.543947 7-year survival rate 0.610698 aneuploid tumors 0.485651 low malignant potential 0.549837 gross residual disease 0.749508 tumor recurrence 0.473805 so-called invasive implants 0.548607 low malignant potential. 0.544407 invasive tumors 0.531513 negative lymph nodes 0.509204 radiation therapy alters 0.492888 borderline tumor 0.475678 d’Obstetrique Annual Report 0.515222 tumor reductive surgery 0.541448 aneuploid invasive implants 0.511492 invasive implants 0.72297 life table analysis 0.517429 tumors 0.678345 completely resected tumor 0.568634 residual tumor 0.843362 large prospective study. 0.509685	CLICK HERE
1526	National Cancer Institute	Html	en	Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of nasopharyngeal cancer.	clinical trial 0.341084 treatment 0.278725 clinical trial search 0.201632 cancer clinical trials 0.224875 lymph nodes 0.503913 radiation therapy 0.653094	National Cancer Institute 0.229813 cancer 0.952582 nasopharyngeal cancer 0.779979 clinical trials 0.675026 affected lymph nodes 0.35443	CLICK HERE
1575	National Cancer Institute	Html	en	Primary CNS Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of primary CNS lymphoma.	treatment 0.59441 malignant tumor cells 0.410902 cancer treatment 0.387562 magnetic resonance imaging 0.302981 AIDS-Related Lymphoma Treatment 0.38242 cancer cells 0.552497 diagnose primary CNS 0.376869 cancer spreads 0.314799 body 0.390696 chemotherapy 0.325347 Cancer Information Service 0.293659 PDQ cancer information 0.395799 treatment clinical trials 0.330856 National Cancer Institute 0.418327 clinical trials 0.79992 spinal cord 0.477649 normal cells 0.306785 CNS lymphoma spreads 0.36676 cancer information summary 0.355271 high-dose chemotherapy 0.312805 clinical trial 0.527292 lymph vessels 0.292112 new treatment 0.386702	stem cell transplant 0.3294 detailed pictures 0.29332 patients 0.363752 external radiation therapy 0.330212 blood 0.30715 nuclear magnetic resonance 0.30502 bone marrow 0.337702 PDQ summary 0.321843 brain radiation therapy 0.396953 treatment clinical trial 0.299448 lymphoma cells 0.314276 NCI PDQ cancer 0.30844 tests 0.319628 primary intraocular lymphoma 0.315344 cancer clinical trials 0.309551 metastatic CNS lymphoma 0.367075 radiation therapy 0.605061 treatment options 0.328184 Treatment Editorial Board 0.31416 primary cns 0.98741 cancer 0.865897 standard treatment 0.301659 positron emission tomography 0.306717	CLICK HERE
1757	National Cancer Institute	Html	en	Biological Therapies for Cancer	A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies.	red blood cells 0.577776 cancer vaccines 0.49997 certain cells 0.540439 human cells 0.554952 healthy cells 0.559468 immune responses 0.496164 dendritic cells 0.583067 white blood cells 0.751432 activated T cells 0.553284 Targeted Cancer Therapies 0.4932 clinical trials 0.665835 anticancer immune response 0.557063 reproductive cells 0.533783 cancer treatment vaccines 0.521084 stem cells 0.582774 biological therapies 0.676853 biological therapy 0.585141 gene therapy 0.624656 cancer cell surface 0.49085 metastatic breast cancer 0.502756 blood-forming stem cells 0.552734 dead cells 0.564287 oncolytic viruses 0.562901 oncolytic virus therapy 0.524139 breast cancer cells 0.605883	abnormal cells 0.587571 non-Hodgkin lymphoma cells 0.585453 receptor-modified T cells 0.533588 Severe allergic reaction 0.495224 cancer cells 0.939837 killer T cells 0.545739 tumour cells 0.53329 immune response 0.649552 antibody-producing cells 0.554007 blood stem cells 0.57668 tumor cells 0.642236 normal cells 0.598729 identical daughter cells 0.56732 immune cells 0.615338 bladder cancer cells 0.599791 laboratory-grown T cells 0.538366 natural killer cells 0.629042 cells 0.962945 cancer clinical trials 0.496931 cytotoxic t cells 0.651132 et al 0.571194 genetically modified cells 0.552195 hematopoietic stem cells 0.563457 immortal hybridoma cells 0.568993	CLICK HERE
1776	National Cancer Institute	Html	es	La nutrición en el tratamiento del cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las causas y el tratamiento de los problemas de nutrición que se presentan en pacientes de cáncer.	Oncology Nutrition Dietetic 0.794305 Nutrition risk screening 0.380015 Perioperative nutrition support 0.325434 August DA 0.321534 Bergerson S 0.42802 medical oncology patients 0.319644 American Cancer Society 0.354235 Malnutrition Screening Tool 0.336109 American Society 0.333545 Adult Oncology Patient 0.321746 Cancer Res 0.323371 nutrition interventions across 0.325357 Leser M 0.456946 cancer patients 0.534602 Hematol Oncol Clin 0.319076 Enteral Nutrition 0.453095 oncology patient 0.475881 Parenter Enteral Nutr 0.377081 Nutrition Risk Screening-2002 0.325017 nutrition therapy 0.376862 pacientes quizás 0.322377 Nutrition Dietetic Practice 0.754692 Medical nutrition therapy 0.368433 Subjective Global Assessment 0.322733 terapia nutricional 0.340919	surgical oncology patients 0.340122 clinical practice 0.555659 Radiation Oncology Nursing 0.334481 Care Cancer 0.324544 Academy’s Oncology Nutrition 0.372909 Dietetic Practice Group 0.607536 nutrition risk 0.383416 Modern Nutrition 0.321534 Oncology Nutrition Evidence 0.344953 Oncology Nursing Practice 0.345995 Top Clin Nutr 0.321751 Nutrition assessment 0.344971 nutrition impact symptoms 0.345866 Clin Nutr 0.326461 cancer cachexia 0.388006 Clinical Nutrition 0.351661 Clin Oncol 0.323666 nutrition support therapy 0.32555 Ledesma N 0.427589 Oncology Nursing Society 0.390831 Oncology Nutrition 0.930511 Oncology Nursing 0.416659 Patient-Generated Subjective Global 0.319243 Nutrition management 0.340043	CLICK HERE
1848	National Cancer Institute	Html	es	Tratamiento del cáncer de piel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de piel.	Compton CC 0.427006 ángulo nariz-mejilla 0.312075 Cutaneous squamous 0.410175 criocirugía frente 0.310658 skin cancers 0.337834 señalización tipo erizo 0.316126 basal-cell carcinoma 0.31436 American Cancer Society 0.31065 Casciato DA 0.3104 7th ed 0.425796 Dermatol Surg Oncol 0.322688 TFD frente 0.31135 cutaneous carcinomas 0.448478 Mohs surgery is 0.310939 Plast Reconstr Surg 0.318551 carcinomas cutáneos 0.316845 Estados Unidos 0.319384 Natl Cancer Inst 0.311163 human papillomavirus infection 0.320874 CCE invasor 0.312649 Euros frente 0.310849 N2a Metástasis 0.310265 cell carcinomas 0.926899 escisión frente 0.315633 Arch Dermatol 0.342458	Carcinoma apocrino 0.319357 uncomplicated basal cell 0.313087 Invest Dermatol 0.31893 Mohs micrographic surgery 0.311178 micosis fungoide 0.313548 Cancer Staging Manual 0.594205 recidivas locales 0.316877 PDQ Tratamiento 0.321192 New York 0.409746 Day CL Jr 0.315276 clasificación tnm 0.310941 células escamosas cutáneos 0.311636 Dermatol Surg 0.324225 Byrd DR 0.419056 T2b Tumor 0.314992 Karagas MR 0.311264 basal cell carcinomas 0.750035 American Joint Committee 0.344157 párpadoa aReproducción 0.326393 tumor fotosensibilizadores 0.313881 Tis Carcinoma 0.334823 Carcinoma arising 0.318249 AJCC Cancer Staging 0.604512 Edge SB 0.427178	CLICK HERE
1878	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) masculino (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) masculino.	Giordano SH 0.546628 Italian Oncology Group 0.503266 aromatase inhibitors 0.504835 Sin embargo 0.505052 accessed october 0.502081 American Cancer Society 0.521913 sumario tratamiento 0.50893 PALB2 mutations 0.502161 Terapia sistémica preoperatoria 0.504717 Instituto Nacional 0.507139 Vlamis V 0.505558 male breast 0.773618 DeVita VT Jr 0.502939 Wong GY 0.505822 population-based study 0.506079 carcinoma lobulillar 0.502812 hereditary male breast 0.514858 estadificación tnm 0.502579 Buzdar AU 0.511225 breast carcinoma 0.529746 German Breast Group 0.523976 Adjuvant therapy with 0.503518 male breast carcinoma 0.523697 Cancer Facts 0.511201 parientes mujeres 0.50281	tumores pten 0.506695 Cancer Res Treat 0.581998 National Cancer Institute 0.509524 or without gonadotropin-releasing 0.502999 PDQ Tratamiento 0.571327 versus ia 0.508803 Hortobagyi GN 0.519998 Intern Med 0.505973 cancer susceptibility 0.510328 cases from 0.502419 metastatic breast 0.510618 Clin Oncol 0.505305 IA vs 0.504284 Physician Data Query 0.502682 breast cancer 0.966614 estadios tnm 0.502728 Oncology Group Phase 0.503374 Aromatase inhibitors with 0.503642 PDQ Sofocos 0.507587 Current management 0.505493 Oncology Group 0.504752 Borgen PI 0.505535 Hormonal treatment 0.502423 Breast Cancer Res 0.608904	CLICK HERE
2031	National Cancer Institute	Html	es	Tratamiento de la enfermedad trofoblástica de la gestación (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la enfermedad trofoblástica de la gestación.	Glándula tiroidea hiperactiva 0.562015 maligna.Molas invasoras 0.545444 siguientes procedimientos 0.560552 estadio iv 0.537226 siguientes aspectos 0.546924 tumores trofoblásticos epitelioides 0.805684 molas invasoras 0.909175 vía oral 0.5248 rayos x 0.529833 enlace drugs approved 0.541637 gonadotropina coriónica huma 0.544512 Gestational Trophoblastic Disease 0.542392 National Cancer Institute 0.526399 ecografía transvaginal 0.535921 siguientes riesgos 0.522487 Instituto Nacional 0.591908 áreas anormales.ampliar examen 0.55209	cuerpo elabora hormona 0.593063 PDQ Tratamiento 0.555876 gestación causa efectos 0.735263 molares.ampliar dilatación 0.527024 partes distantes 0.78863 siguientes factores 0.551671 Physician Data Query 0.592879 estadio i 0.537379 último panel 0.524777 estadio iii 0.537123 término enfermedad 0.57453 siguientes operaciones 0.536826 histerectomía laparoscópica total.Ampliar 0.550873 siguientes enlaces 0.525533 histerectomía abdominal 0.531238 siguientes pruebas 0.60278	CLICK HERE
16843	National Cancer Institute	Html	en	Massachusetts General Hospital and Harvard Univeristy — Imaging of Nanotherapeutic Drug Action	In vivo imaging analyses of therapeutic nanoparticles (TNP), addressing key questions on nanoparticle distribution (pharmacokinetics, PK) and cellular response (pharmacodynamics, PD).	nanoparticle distribution 0.841511 enhanced MR imaging 0.924949 biological understanding 0.766676 Alliance members 0.763245 M.D. 0.664358 vivo imaging analyses 0.983793 Claudio Vinegoni 0.829503 Cesar Castro 0.816804 cancer cells 0.772225 NCI Alliance 0.790962 Ph.D 0.666483 project team 0.768015 considerable proportion 0.780069 clinical data 0.766134 recent developments 0.775301 multimodality imaging 0.800032 larger number 0.783733 affinity ligands 0.782978 cancer nanotechnology questions 0.94124 Ralph Weissleder 0.799712 TNP 0.654222 free survival 0.789955 vivo imaging technologies 0.994916 nano-encapsulated chemotherapeutics 0.788661	recent feasibility studies 0.924078 lower toxicity 0.785357 cancer members 0.792525 molecular diagnostics 0.779336 new strategy 0.77113 following questions 0.766532 new constructs 0.797665 new biological insight 0.926895 vivo setting 0.83945 tumoral accumulation 0.816621 temporal heterogeneity 0.803444 key questions 0.775023 future interactions 0.756886 efficacy 0.740414 tumoral myeloid cells 0.915593 Principal Investigators 0.797013 tumor cell accumulation 0.959124 therapeutic nanoparticles 0.774355 molecular / cell 0.763144 occasionally improved progression 0.958519 Mikael Pittet 0.837942 cancer biology 0.77172 Alliance projects 0.764335	CLICK HERE
17186	National Cancer Institute	Html	en	TMIST (Tomosynthesis Mammographic Imaging Screening Trial)	TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).	routine screening mammogram 0.506393 entire study group 0.421549 tomosynthesis mammography 0.449515 health plans 0.41281 3-D mammography 0.660743 trial 0.465454 breast cancer status 0.514295 standard digital mammography 0.512193 3-D mammogram 0.462356 women ages 0.504522 following factors 0.42666 breast biopsies 0.439927 fewer false-positive test 0.416422 researchers 0.394009 2-D screening mammograms 0.502737 mammography clinics 0.435449 aggressive breast cancers 0.493477 ECOG-ACRIN Cancer Research 0.42875 2-D mammography 0.505053 3-D mammograms 0.447984 hormone replacement therapy 0.765582 randomized breast 0.472367 personal risk factors 0.42803 primary care doctors 0.417168 women 0.662197	risk changes 0.412147 fewer harder-to-treat cancers 0.422139 study 0.460399 best ways 0.450667 mammograms 0.529145 age group 0.430585 certain groups 0.456471 breast cancers 0.534289 dense breasts 0.527755 complete cost 0.412269 premenopausal women 0.386263 routine mammogram 0.443785 mammogram 0.569066 3-D mammography machines 0.510266 3-D mammography images 0.549905 breast cancer screening 0.609852 newly diagnosed breast 0.491574 nearby lymph node 0.415404 breast cancer 0.940336 trial record 0.381013 tissue samples 0.430822 genetic changes 0.428717 Women’s health 0.38389 family history 0.510755	CLICK HERE